Listar por autor "Duparc, Stephan"

Mostrando ítems 1-4 de 4

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Llanos Cuentas, Elmer Alejandro; Casapia, Martin; Chuquiyauri, Raúl; Hinojosa, Juan-Carlos; Kerr, Nicola; Rosario, Maria; Toovey, Stephen; Arch, Robert H.; Phillips, Margaret A.; Rozenberg, Felix D.; Bath, Jade; Ng, Caroline L.; Cowell, Annie N.; Winzeler, Elizabeth A.; Fidock, David A.; Baker, Mark; Möhrle, Jörg J.; Hooft van Huijsduijnen, Rob; Gobeau, Nathalie; Araeipour, Nada; Andenmatten, Nicole; Rückle, Thomas; Duparc, Stephan (Elsevier, 2018)

BACKGROUND: DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. ...
Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping

Beck, Hans-Peter; Wampfler, Rahel; Carter, Nick; Koh, Gavin; Osorio, Lyda; Rueangweerayut, Ronnatrai; Krudsood, Srivcha; Lacerda, Marcus V.; Llanos Cuentas, Elmer Alejandro; Duparc, Stephan; Rubio, Justin P.; Green, Justin A. (Oxford University Press, 2015)

UNLABELLED: Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, ...
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study

Llanos Cuentas, Elmer Alejandro; Lacerda, Marcus V.; Rueangweerayut, Ronnatrai; Krudsood, Srivicha; Gupta, Sandeep K.; Kochar, Sanjay K.; Arthur, Preetam; Chuenchom, Nuttagarn; Möhrle, Jörg J.; Duparc, Stephan; Ugwuegbulam, Cletus; Kleim, Jörg-Peter; Carter, Nick; Green, Justin A.; Kellam, Lynda (Elsevier, 2014)

BACKGROUND: Clinical effectiveness of previous regimens to treat Plasmodium vivax infection have been hampered by compliance. We aimed to assess the dose-response, safety, and tolerability of single-dose tafenoquine plus ...
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

St-Jean, Pamela-L.; Xue, Zhengyu; Carter, Nick; Koh, Gavin-C. K. W.; Duparc, Stephan; Taylor, Maxine; Beaumont, Claire; Llanos Cuentas, Elmer Alejandro; Rueangweerayut, Ronnatrai; Krudsood, Srivicha; Green, Justin-A.; Rubio, Justin-P. (BioMed Central, 2016)

Background: Tafenoquine (TQ) and primaquine (PQ) are 8-aminoquinolines (8-AQ) with anti-hypnozoite activity against vivax malaria. PQ is the only FDA-approved medicine for preventing relapsing Plasmodium vivax infection ...

Listar por autor "Duparc, Stephan"

Listar por autor "Duparc, Stephan"

Buscar en el Repositorio

Listar

Todo el Repositorio

Panel de Control